PDF(Pubmed)
Abstract：
BACKGROUND: Dyspepsia is a common gastrointestinal illness sometimes associated with Helicobacter pylori (H. pylori) infection. Screening and eradicating the bacterium reduces the risk of infection-related complications. The aim of this study was to determine the magnitude of H. pylori infection among dyspeptic patients and the effectiveness of triple eradication therapy at hospitals in Hawassa city, Ethiopia.
RESULTS: The prevalence of H. pylori infection was 48.5%. The H. pylori eradication rate using first-line triple therapy was 83.8%. Eradication therapy failure is associated with previous exposure compared to no exposure (AOR: 4.8, 95% CI: 1.37-10.97), a regimen for 10-days compared to 14-days (AOR: 4.05, 95% CI: 1.42-11.55), and self-reported side effects compared to no report (AOR: 2.5, 95% CI: 1.12-5.97). Based on Morisky-eight scale 230 (79.0%) patients were adherent to their triple therapy. Participants with no reports of adverse effects showed increased odds of adherence to triple therapy compared to those who had reports (AOR = 2.45, 95% CI: 1.29-4.62).
CONCLUSIONS: This study demonstrated that about half of adult dyspeptic patients were infected with H. pylori, and moderate eradication was observed. Factors such as previous history of eradication therapy, duration of the eradication regimen, and perception of potential adverse effects are associated with eradication rate and should be considered during the initiation of eradication therapy.
RESULTS: The prevalence of H. pylori infection was 48.5%. The H. pylori eradication rate using first-line triple therapy was 83.8%. Eradication therapy failure is associated with previous exposure compared to no exposure (AOR: 4.8, 95% CI: 1.37-10.97), a regimen for 10-days compared to 14-days (AOR: 4.05, 95% CI: 1.42-11.55), and self-reported side effects compared to no report (AOR: 2.5, 95% CI: 1.12-5.97). Based on Morisky-eight scale 230 (79.0%) patients were adherent to their triple therapy. Participants with no reports of adverse effects showed increased odds of adherence to triple therapy compared to those who had reports (AOR = 2.45, 95% CI: 1.29-4.62).
CONCLUSIONS: This study demonstrated that about half of adult dyspeptic patients were infected with H. pylori, and moderate eradication was observed. Factors such as previous history of eradication therapy, duration of the eradication regimen, and perception of potential adverse effects are associated with eradication rate and should be considered during the initiation of eradication therapy.
摘要：
背景：消化不良是一种常见的胃肠道疾病，有时与幽门螺杆菌有关（H.幽门螺杆菌)感染。筛选和根除细菌可降低感染相关并发症的风险。这项研究的目的是确定消化不良患者中幽门螺杆菌感染的程度以及Hawassa市医院三联根除疗法的有效性。埃塞俄比亚。
结果：幽门螺杆菌感染率为48.5%。一线三联疗法的幽门螺杆菌根除率为83.8%。根除治疗失败与以前的暴露有关（AOR：4.8，95％CI：1.37-10.97），与14天相比，10天的治疗方案（AOR：4.05，95％CI：1.42-11.55），与无报告相比，自我报告的副作用（AOR：2.5，95％CI：1.12-5.97）。根据Morisky-8量表，230名（79.0％）患者坚持其三联疗法。没有不良反应报告的参与者与有报告的参与者相比，坚持三联疗法的几率增加（AOR=2.45，95％CI：1.29-4.62）。
结论：这项研究表明，大约一半的成人消化不良患者感染了幽门螺杆菌，观察到中度根除。以前的根除治疗史等因素，根除方案的持续时间，对潜在不良反应的感知与根除率相关，在开始根除治疗时应予以考虑。
结果：幽门螺杆菌感染率为48.5%。一线三联疗法的幽门螺杆菌根除率为83.8%。根除治疗失败与以前的暴露有关（AOR：4.8，95％CI：1.37-10.97），与14天相比，10天的治疗方案（AOR：4.05，95％CI：1.42-11.55），与无报告相比，自我报告的副作用（AOR：2.5，95％CI：1.12-5.97）。根据Morisky-8量表，230名（79.0％）患者坚持其三联疗法。没有不良反应报告的参与者与有报告的参与者相比，坚持三联疗法的几率增加（AOR=2.45，95％CI：1.29-4.62）。
结论：这项研究表明，大约一半的成人消化不良患者感染了幽门螺杆菌，观察到中度根除。以前的根除治疗史等因素，根除方案的持续时间，对潜在不良反应的感知与根除率相关，在开始根除治疗时应予以考虑。
